On November 16, 2020 Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, reported that Company management will participate at two upcoming virtual conferences (Press release, Atara Biotherapeutics, NOV 16, 2020, View Source [SID1234574477]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Stifel 2020 Virtual Healthcare Conference
Wednesday, November 18, 2020 at 4:40 p.m. EST
Fireside Chat with Pascal Touchon, President and Chief Executive Officer
Evercore ISI 3rd Annual Virtual HealthCONx Conference
Wednesday, December 2, 2020 at 8:50 a.m. EST
Fireside Chat with Pascal Touchon and Jakob Dupont, Global Head of Research and Development
Live video webcasts of both presentations will be available by visiting the Investor Events and Presentations section of atarabio.com. Archived replays will be available on the Company’s website for approximately 14 days following the live webcasts.